13 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
25987375	20	Discovery of a novel Kv7 channel opener as a treatment for epilepsy.	Pfizer
25017033	148	Potent and selective inhibitors of the TASK-1 potassium channel through chemical optimization of a bis-amide scaffold.	University Of Kansas Specialized Chemistry Center
23121096	86	Ion channels as therapeutic targets: a drug discovery perspective.	Pfizer
20020710	30	Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.	Icagen
22793372	66	Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.	Vanderbilt University Medical Center
22770500	219	3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models.	Astrazeneca
22910039	66	Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator.	Vanderbilt University Medical Center
24900334	89	N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.	TBA
17483457	58	A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.	Abbott Laboratories
12930139	22	Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.	Bristol-Myers Squibb Pharmaceutical Research Institute
21296466	20	Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.	Hebei Medical University
20855211	91	Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives.	Abbott Laboratories
12852750	2	(S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine.	Bristol-Myers Squibb Pharmaceutical Research Institute